Annual Review of Cancer Biology · 2018 · 13 citations · 58 references
MedicineImmunologyOncologyAdaptive ImmunityImmunizationVaccinologyAdaptive Immune ResponsesCancer ImmunotherapyCancer VaccinesOncogenic VirusesVaccinationVaccine-preventable DiseasesCancer Vaccine DesignCancer Vaccine DevelopmentPreventive Oncology VaccinesPreventive VaccinationProphylactic Cancer VaccinesProphylactic Vaccine DevelopmentProphylactic VaccinesTumor Immunogenicity
The successful development of prophylactic cancer vaccines targeting oncogenic viruses has demonstrated the potential for vaccination to reduce the global burden of cancer. However, most human cancers are not caused by viruses, and therefore novel approaches are needed for the successful development of prophylactic cancer vaccines for nonviral cancers. In this review, we detail evidence that the human immune system can recognize and eliminate non-virus-caused cancers before they become clinically apparent. We also discuss the design of an ideal prophylactic vaccine with the goal of providing a lasting adaptive immune response against antigen targets that arise early in a cancer's development.
58
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Philip W. Kantoff, Celestia S. Higano, Neal D. Shore et al. · New England Journal of Medicine · 2010 · 5.5K citations · Full text
Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Lijun Sun, Jiaxi Wu, Fenghe Du et al. · Science · 2012 · 4.8K citations
Cancer immunotherapy: moving beyond current vaccines
Steven A. Rosenberg, James C. Yang, Nicholas P. Restifo · Nature Medicine · 2004 · 3K citations · Full text
Medicine, Immunology, Oncology +14
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Vijay Shankaran, Hiroaki Ikeda, Allen T. Bruce et al. · Nature · 2001 · 2.8K citations
Life Sciences, Immunology, Oncology +12